Stifel Nicolaus Increases Nyxoah (NASDAQ:NYXH) Price Target to $27.00

Nyxoah (NASDAQ:NYXHGet Free Report) had its price objective upped by equities research analysts at Stifel Nicolaus from $20.00 to $27.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 81.33% from the stock’s previous close.

NYXH has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Nyxoah in a research report on Wednesday, March 6th. Cantor Fitzgerald boosted their price objective on Nyxoah from $10.00 to $14.00 and gave the stock an “overweight” rating in a research report on Friday, February 9th. Oppenheimer boosted their target price on Nyxoah from $17.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, March 14th. Finally, Piper Sandler upped their price target on Nyxoah from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $20.60.

Get Our Latest Stock Report on NYXH

Nyxoah Stock Performance

Nyxoah stock opened at $14.89 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.50. The stock has a fifty day moving average of $12.17 and a two-hundred day moving average of $8.06. Nyxoah has a fifty-two week low of $4.00 and a fifty-two week high of $20.00.

Nyxoah (NASDAQ:NYXHGet Free Report) last posted its quarterly earnings data on Tuesday, March 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). Nyxoah had a negative return on equity of 38.58% and a negative net margin of 993.28%. The business had revenue of $1.96 million for the quarter, compared to analysts’ expectations of $2.01 million. As a group, analysts forecast that Nyxoah will post -1.78 earnings per share for the current fiscal year.

Institutional Trading of Nyxoah

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. ExodusPoint Capital Management LP grew its holdings in Nyxoah by 44.6% during the 2nd quarter. ExodusPoint Capital Management LP now owns 18,758 shares of the company’s stock worth $150,000 after acquiring an additional 5,787 shares during the period. JPMorgan Chase & Co. bought a new stake in Nyxoah in the 1st quarter valued at $965,000. AXA S.A. lifted its position in Nyxoah by 1.4% in the 1st quarter. AXA S.A. now owns 217,000 shares of the company’s stock valued at $1,621,000 after acquiring an additional 3,000 shares in the last quarter. Millennium Management LLC bought a new stake in Nyxoah in the 4th quarter valued at $51,000. Finally, Sei Investments Co. bought a new stake in Nyxoah in the 2nd quarter valued at $265,000.

About Nyxoah

(Get Free Report)

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.

Featured Articles

Analyst Recommendations for Nyxoah (NASDAQ:NYXH)

Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.